Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Adamic

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
The Canadian Journal of Hospital Pharmacy|March 31, 2023
A Framework for Evaluating the Implementation of Biosimilar DrugsLisa Milgram, Sarah Wheeler, Andrea Adamic, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 10, 2024
Cost-Effectiveness Analysis of Bevacizumab Biosimilars Versus Originator Bevacizumab for Metastatic Colorectal Cancer: A Comparative Study Using Real-World DataBrandon Lu, Erind Dvorani, Lena Nguyen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 27, 2024
Comparative Safety and Effectiveness of Bevacizumab Biosimilars to Originator for the Treatment of Metastatic Colorectal CancerCaroline Muñoz, Jaclyn M Beca, Erind Dvorani, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
The Canadian Journal of Hospital Pharmacy|March 31, 2023
A Framework for Evaluating the Implementation of Biosimilar DrugsLisa Milgram, Sarah Wheeler, Andrea Adamic, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 10, 2024
Cost-Effectiveness Analysis of Bevacizumab Biosimilars Versus Originator Bevacizumab for Metastatic Colorectal Cancer: A Comparative Study Using Real-World DataBrandon Lu, Erind Dvorani, Lena Nguyen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 27, 2024
Comparative Safety and Effectiveness of Bevacizumab Biosimilars to Originator for the Treatment of Metastatic Colorectal CancerCaroline Muñoz, Jaclyn M Beca, Erind Dvorani, et al.
Pageof 1